SCHEMBL538056

SCHEMBL538056

CSCCC(N)C(=O)NCC(=O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
PTGS2 P35354 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
RNPEP Q9H4A4 1/20 0.44
CTSC P53634 1/20 0.43
FNTA P49354 3/20 0.42
FNTB P49356 3/20 0.42
PGGT1B P53609 2/20 0.42
ARG1 P05089 1/20 0.41
ARG2 P78540 1/20 0.41
PTGS1 P23219 1/20 0.40
GSTK1 Q9Y2Q3 1/20 0.40
MMP2 P08253 3/20 0.40
ECE1 P42892 1/20 0.40
DPP7 Q9UHL4 2/20 0.39
MME P08473 1/20 0.39
ACE P12821 1/20 0.39
CPA1 P15085 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL538055 1.00 ALDH1A1 (0.44) ALDH1A1LMNAMAPTPTGS2TDP1
Hydrochloric Acid SCHEMBL28446971 0.98 ALDH1A1 (0.43) ALDH1A1LMNAMAPTPTGS2TDP1
Hydrochloric Acid SCHEMBL28446972 0.98 ALDH1A1 (0.43) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL29350823 0.94 MMP2 (0.41) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL30052506 0.88 TSHR (0.47) LMNAFNTAFNTBPGGT1BPTGS1
SCHEMBL30052913 0.88 METAP2 (0.43) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL8000185 0.87 FNTA (0.48) FNTAFNTBPGGT1BPTGS1GSTK1
SCHEMBL8000193 0.87 FNTA (0.48) FNTAFNTBPGGT1BPTGS1GSTK1
SCHEMBL30052468 0.85 FNTA (0.43) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL30590002 0.85 PTGS1 (0.42) ALDH1A1LMNAMAPTPTGS2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12397012-B2 Nucleic acid therapeutics for genetic disorders GREENLIGHT BIOSCIENCES, INC. (US) 2025-08-26 US claimed
CN-116171326-A Nucleic acid therapy for genetic disorders 绿光生物科技股份有限公司 2023-05-26 CN claimed
EP-4182332-A1 NUCLEIC ACID THERAPEUTICS FOR GENETIC DISORDERS Greenlight Biosciences, Inc. (US) 2023-05-24 EP claimed
US-20220096525-A1 NUCLEIC ACID THERAPEUTICS FOR GENETIC DISORDERS GREENLIGHT BIOSCIENCES, INC. 2022-03-31 US claimed
US-20160374380-A1 SALTY TASTE ENHANCER T. HASEGAWA CO., LTD. (JP) 2016-12-29 US claimed
US-4095000-A AMINO ACIDS AND DERIVATIVES, POLYHYDROXY COMPOUNDS, NUTRIENTS, HYDROLYSIS Brenner, Max (CH) 1978-06-13 US claimed
US-3959519-A Fortification of food materials with a methionine source E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-05-25 US claimed
WO-2026089754-A1 COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES Finitus, LLC (US) 2026-04-30 WO disclosed
WO-2026089752-A1 COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES Finitus, LLC (US) 2026-04-30 WO disclosed
US-20260108467-A1 COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES FINITUS LLC (US) 2026-04-23 US disclosed
US-20260108583-A1 COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES FINITUS LLC (US) 2026-04-23 US disclosed
US-20260036547-A1 METHODS FOR DETECTING METABOLITES USING A MICROFLUIDIC-BASED CE-MS SYSTEM ASTRAZENECA AB (SE) 2026-02-05 US disclosed
US-12397012-B2 Nucleic acid therapeutics for genetic disorders GREENLIGHT BIOSCIENCES, INC. (US) 2025-08-26 US disclosed
US-4303692-A TAURINE ADDITIVE ABBOTT LABORATORIES 1981-12-01 US disclosed
US-4235942-A LOW MOLECULAR WEIGHT POLYAMINO ACIDS FOR NUTRITIONAL FORTIFICATION STANDARD OIL COMPANY (INDIANA) (US) 1980-11-25 US disclosed
EP-0015668-A1 Digestible polyamino acids, method for preparing them and food fortified with the digestible polyamino acids Standard Oil Company (US) 1980-09-17 EP disclosed
US-4095000-A AMINO ACIDS AND DERIVATIVES, POLYHYDROXY COMPOUNDS, NUTRIENTS, HYDROLYSIS Brenner, Max (CH) 1978-06-13 US disclosed
US-4024286-A Fortification of foodstuffs with C-terminal amino acid substituted methionine dipeptides MILES LABORATORIES, INC. (US) 1977-05-17 US disclosed
US-3959519-A Fortification of food materials with a methionine source E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-05-25 US disclosed
US-3959519-A Fortification of food materials with a methionine source E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260108583-A1 COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES MUC1, VIP, LGALS4 ALDH1A1 3706/4885LMNA 1681/4885MAPT 2398/4885
US-20260108467-A1 COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES FGF23, FIBP, PTMS ALDH1A1 2847/4885LMNA 3506/4885MAPT 1252/4885
US-20260036547-A1 METHODS FOR DETECTING METABOLITES USING A MICROFLUIDIC-BASED CE-MS SYSTEM ATP5ME, ATP5MF, ATP5MK ALDH1A1 1687/4885LMNA 3325/4885MAPT 3490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.